HCW Biologics Poster Presentation at AACR Annual Meeting 2023
April 13, 2023 07:15 ET
|
HCW Biologics, Inc
Presentation of data for the mechanism underlying HCW9218 against solid tumors HCW9218 is the clinical-stage, lead product candidate of HCW Biologics Inc. MIRAMAR, Fla., April 13, 2023 (GLOBE...
HCW Biologics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
March 28, 2023 16:25 ET
|
HCW Biologics, Inc
MIRAMAR, Fla., March 28, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and...
Sotera Health Company (SHC) Class Action Alert: Contact Robbins LLP for Information Regarding the Class Action Against Sotera Health Company
February 10, 2023 13:29 ET
|
Robbins LLP
SAN DIEGO, Feb. 10, 2023 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all investors who purchased or otherwise acquired Sotera...
Shareholder Alert: Robbins LLP Reminds Investors of Class Action Against Sotera Health Company (SHC)
January 30, 2023 16:09 ET
|
Robbins LLP
SAN DIEGO, Jan. 30, 2023 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all investors who purchased or otherwise acquired...
HCW Biologics is Granted Second Fundamental Patent: U.S. Patent for Multi-Chain Chimeric Polypeptide Created with TOBI™ Platform
December 07, 2022 07:30 ET
|
HCW Biologics, Inc
Allowed Claims for Novel Immunotherapeutic Compound Constructed with Tissue Factor as Platform for Target Binding Domains Patent for Underlying Intellectual Property for HCW9218 Currently in Clinical...
Zenith Epigenetics Announces Start of Several National Cancer Institute (NCI)-Sponsored Oncology Clinical Trials
July 06, 2022 07:12 ET
|
Zenith Capital Corp.
CALGARY, Alberta, July 06, 2022 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today that its leading BET inhibitor, ZEN-3694, is being evaluated in seven NCI...
Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the American Society of Clinical Oncology Conference (ASCO)
June 21, 2022 07:12 ET
|
Zenith Capital Corp.
CALGARY, Alberta, June 21, 2022 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today that the data from its Phase 2 Metastatic Triple Negative Breast Cancer...
The Foundation of Hope and Innovation Partners with Venice Family Clinic to Provide Free Mammograms
May 24, 2022 17:30 ET
|
The Foundation of Hope and Innovation
CERRITOS, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- The Foundation of Hope and Innovation, a charity supported by The Oncology Institute, Inc. (NASDAQ: TOI), announced a $40,000 donation to Venice...
LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results
March 24, 2022 06:30 ET
|
LAVA Therapeutics N.V.
LAVA-051 shows encouraging initial safety and pharmacodynamic observations; on track for more dose escalation data from Phase 1/2a trial in Q2 2022LAVA-1207 Phase 1/2a trial in mCRPC on track to...
LAVA Therapeutics To Present at the Oppenheimer 32nd Annual Healthcare Conference 2022
March 10, 2022 06:30 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, March 10, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary...